Surgery Partners (NASDAQ:SGRY) Earns “Outperform” Rating from Macquarie

Macquarie reissued their outperform rating on shares of Surgery Partners (NASDAQ:SGRY) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.

Several other research analysts have also issued reports on the company. Citigroup decreased their target price on Surgery Partners from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $49.00 target price on shares of Surgery Partners in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $43.00 price target on shares of Surgery Partners in a research note on Friday, October 4th. UBS Group started coverage on Surgery Partners in a research note on Monday, October 14th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Benchmark restated a “buy” rating and issued a $50.00 price target on shares of Surgery Partners in a research note on Monday, August 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.71.

Surgery Partners Trading Up 4.2 %

SGRY opened at $22.75 on Tuesday. The business has a 50 day simple moving average of $30.45 and a two-hundred day simple moving average of $28.46. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -47.40, a PEG ratio of 16.86 and a beta of 2.76. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. Surgery Partners has a one year low of $21.36 and a one year high of $36.92.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.06). Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The firm had revenue of $770.40 million during the quarter, compared to the consensus estimate of $768.99 million. During the same period in the prior year, the company posted $0.15 EPS. The firm’s revenue was up 14.3% on a year-over-year basis. Analysts predict that Surgery Partners will post 0.83 EPS for the current year.

Institutional Trading of Surgery Partners

Institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP boosted its stake in Surgery Partners by 12.2% during the 3rd quarter. Royce & Associates LP now owns 510,261 shares of the company’s stock valued at $16,451,000 after purchasing an additional 55,545 shares during the last quarter. Bamco Inc. NY boosted its stake in Surgery Partners by 100.0% during the 1st quarter. Bamco Inc. NY now owns 90,000 shares of the company’s stock valued at $2,685,000 after purchasing an additional 45,000 shares during the last quarter. Lombard Odier Asset Management Europe Ltd purchased a new stake in Surgery Partners during the 2nd quarter valued at $4,163,000. Rhumbline Advisers boosted its stake in Surgery Partners by 19.6% during the 2nd quarter. Rhumbline Advisers now owns 127,952 shares of the company’s stock valued at $3,044,000 after purchasing an additional 20,963 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Surgery Partners during the 2nd quarter valued at $29,288,000.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.